This clinical trial is designed for men and women with Dynamic International Prognostic Scoring System (DIPSS) intermediate-2 or high risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) who are ineligible for treatment with a Janus kinase (JAK) inhibitor.

The purpose of this study is to evaluate the safety and effectiveness of an investigational new drug Reparixin to treat myelofibrosis. Investigational means Reparixin is not approved by the U.S. Food and Drug Administration (FDA). 

The Alzheimer’s Network (ALZ-NET) is a network of clinicians that will collect information about participants’ treatment and care. The purpose of this study is to enable ALZ-NET to collect long-term data of individuals who are evaluated for or receive treatment with a novel FDA-Approved therapy for Alzheimer's Disease (AD). A novel FDA approved therapy approved therapy for AD is a medication that has been approved by the FDA since 2011 and has Alzheimer's disease listed as an indication with the prescribing instructions.
   

This is a non-interventional longitudinal study of children and adults with Developmental and Epileptic Encephalopathy (DEE) due to a genetic cause. There are six arms of the study.

Arms 1, 2, and 3 are devoted to one example DEE, MEF2C Haploinsufficiency Syndrome (MCHS). Arms 4, 5, and 6 are open to all DEE.

Arm 1 (in-person) will enroll children 0 to 15, who will make in-person visits to Weill Cornell Medicine four times over two years.

This clinical trial is designed for men and women with HER2 positive gastric cancer.
   

This study is being done to evaluate the safety and potential effectiveness of BHV-1510 alone and BHV-1510 in combination with cemiplimab in participants with certain solid tumor cancers. This study will be conducted in 2 parts called “phases.”

This study is for female and male patients who are 18 years of age and older and have Gastric Outlet Obstruction (GOO). GOO is the inability of the stomach to empty its contents into the duodenum.

The primary objective of the study is to evaluate the safety of tobevibart+elebsiran in participants with chronic hepatitis Delta virus (HDV) infection. 

The purpose of this study is to learn more about the daily experiences, including thoughts, feelings, social interactions, medication adherence, and overall health and well-being of gay or bisexual men living with HIV ages 45-64.

There are three study visits:

1. Day 1/screening visit
2. 6 month visit
3. 12 month visit.

Participation will last about 12 months. After the Day 1 study visit, participants are asked to complete a daily diary survey and wear a watch that measures sleep and activity for 30 days.  

The purpose of this study is to evaluate a potential long-acting injectable HIV treatment option for people whose HIV is not undetectable.

The study drug is a long-acting HIV treatment. It is given by injection every other month after 2 started doses. This is in contrast to oral ART, which is designed to be taken daily.

This study is comparing rectal and oral Tenofavir-based prep. The rectal study product is a rectal douche, or enema, that contains the anti-HIV drug tenofovir (TFV). The other study product is taken by mouth and is a combination of two drugs, called emtricitabine (FTC or F) and tenofovir disoproxil fumarate (TDF).

Tenofovir (TFV) rectal douche is considered investigational because it is not approved by the U.S. Food and Drug Administration (FDA). Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) is FDA-approved and used according to FDA labeling.